Hydroxyurea is linked in the source record to MPN; Leukemia (selected cytoreductive use), with the principal indications stated as Myeloproliferative neoplasms such as polycythemia vera and essential thrombocythemia; sickle-cell disease is a non-oncology indication. Its action is described as follows: Inhibits ribonucleotide reductase and reduces deoxyribonucleotide production, impairing DNA synthesis. The drug interferes with nucleotide metabolism or related cellular pathways, limiting the ability of actively dividing tumor cells to synthesize or process essential DNA building blocks. Pharmacologically, it is a ribonucleotide reductase inhibitor and is categorized as Chemotherapy; Antimetabolite. The regimen field identifies Hydroxyurea monotherapy; cytoreduction regimens. The clinical importance of those combinations is that treatment partners can determine how the medicine is positioned within a larger oncology program. Its clinical role is defined by the disease-specific regimen, treatment intent, and patient-selection criteria associated with the listed indications. The indication should be read as a complete clinical statement, particularly where it contains receptor, mutation, stage, prior-treatment, or disease-status requirements. A class label alone cannot establish that a drug is appropriate for a particular patient or tumor. This entry provides an original reference summary based on the supplied clinical fields and does not substitute for current prescribing information. No individualized dose, dose adjustment, or administration instruction is included.